ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2031

Dysregulated NK Cell PLC

Allison A. Throm1, Joshua B. Alinger1, Lauren M. Pachman2 and Anthony R. French3, 1Pediatrics, Washington University St Louis, St Louis, MO, 2Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, 3Pediatric Rheumatology, Washington University St Louis, Saint Louis, MO

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: juvenile dermatomyositis, natural killer (NK) cells and signal transduction

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Pediatric Rheumatology – Basic Science Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Juvenile dermatomyositis (JDM) is a debilitating pediatric autoimmune disease manifesting with characteristic rash and proximal muscle weakness. We investigated signaling abnormalities in immune cell subsets from treatment-naïve JDM patients and healthy controls.

Methods: To delineate signaling abnormalities, mass cytometry coupled with phosphoprotein antibodies was performed with peripheral blood mononuclear cells from seventeen treatment-naïve JDM patients and controls.

Results: The percentages of peripheral NK cells were lower while frequencies of naïve Β cells and naïve CD4 T cells were higher in JDM patients than controls. These cell frequency differences were attenuated in paired patient samples with cessation of active disease. A large number of signaling differences were identified in treatment-naïve JDM patients compared to controls. Classification models incorporating feature selection demonstrated that differences in PLCγ2 phosphorylation comprised 10 of the 12 features (i.e., phosphoprotein in a specific immune cell subset) distinguishing the JDM patients from healthy controls. As NK cells represented 5 of these 12 features, further studies focused on the critical PLCγ2 pathway in NK cells which is responsible for stimulating calcium flux and cytotoxic granule movement. No differences were detected in upstream kinases (Itk/Btk, Syk/ZAP70) or total PLCγ2 protein levels. The decreased phosphorylation of NK cell PLCγ2 and downstream MAPKAPK2 was partially attenuated in treatment-naïve JDM patients with cessation of active disease. Furthermore, suppressed PLCγ2 phosphorylation in treatment-naïve JDM patient NK cells resulted in decreased calcium flux.

Conclusion: The novel identification of dysregulation of PLCγ2 phosphorylation and decreased calcium flux in NK cells from treatment-naïve JDM patients provides potential mechanistic insight into JDM pathogenesis.


Disclosure: A. A. Throm, None; J. B. Alinger, None; L. M. Pachman, None; A. R. French, None.

To cite this abstract in AMA style:

Throm AA, Alinger JB, Pachman LM, French AR. Dysregulated NK Cell PLC [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/dysregulated-nk-cell-plc/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/dysregulated-nk-cell-plc/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology